SCHEMBL3737833

SCHEMBL3737833

CC(C)Oc1ccc(C(=O)C=Cc2ccc(C(F)(F)F)cc2)cc1OC(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 7/20 0.59
CYP1B1 Q16678 7/20 0.59
MAOB P27338 3/20 0.58
PDE4A P27815 1/20 0.57
PDE4B Q07343 1/20 0.57
PDE4C Q08493 1/20 0.57
PDE4D Q08499 1/20 0.57
P4HB P07237 1/20 0.56
CXCL12 P48061 1/20 0.56
ABCG2 Q9UNQ0 4/20 0.54
CYP1A2 P05177 1/20 0.51
TNFRSF1A P19438 1/20 0.50
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3729582 0.94 PDE4A (0.65) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL3734791 0.94 ABCG2 (0.64) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL3737832 0.93 CXCL12 (0.65) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL3729579 0.87 CXCL12 (0.71) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL3734789 0.87 CXCL12 (0.71) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL8175111 0.84 ABCG2 (0.79) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL3735097 0.84 ABCG2 (0.79) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL3743243 0.81 CXCL12 (0.63) CYP1A1CYP1B1MAOBP4HBCXCL12
SCHEMBL3735821 0.81 CYP1A1 (0.72) CYP1A1CYP1B1MAOBPDE4APDE4B
SCHEMBL8160826 0.79 CYP1A1 (0.67) CYP1A1CYP1B1MAOBP4HBCXCL12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114867-B1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HCRTR1, HCRTR2, HRH3 CYP1A1 1184/4885CYP1B1 976/4885MAOB 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.